IGHE and asthma: We conducted a prospective study of up to 3 years of treatment in a real-life setting, focusing on improvement of symptoms and QoL (Sinonasal Outcome Test 22—SNOT-22, visual analogue scale—VAS, nasal congestion score—NCS), endoscopic (nasal polyp score—NPS) and radiological features (Lund–Mackay score—LMS), as well as olfactory function (Sniffin test—SSIT-16), asthma control (ACT) and variation of T2 biomarkers (B-EOS, total IgE and FENO).